Back to News
Market Impact: 0.45
Longeveron's Laromestrocel Misses Primary Endpoint In Phase 2b HLHS Trial; Stock Down 59%
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Longeveron's Phase 2b ELPIS II trial of laromestrocel in infants with hypoplastic left heart syndrome failed its primary endpoint. The therapy did not demonstrate improvement in right ventricular ejection fraction at 12 months, representing a significant clinical-development setback likely to pressure LGVN shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
LGVN-0.90
More News
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”
- Jensen Huang says Nvidia will sell twice as many chips next year
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go
- UK Lawmakers Say Thames Creditors Have Been Joyriding Family Car
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors
- AI Tools for Private Equity Due Diligence: A Buyer Workflow